{"allTrials": {"@totalCount": "25", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2009-06-29T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2009-06-29T00:00:00.000Z", "#text": "80881420"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Implementation of De-Escalation Algorithm in patients with ventilator-associated pneumonia at two anaesthesiological intensive care units (ICUs) of Charit\u00e9 - University Medicine Berlin", "scientificTitle": "Implementation of De-Escalation Algorithm in patients with ventilator-associated pneumonia at two anaesthesiological intensive care units (ICUs) of Charit\u00e9 - University Medicine Berlin: a prospective observational single centre trial", "acronym": "De-Escalation Algorithm", "studyHypothesis": "The implementation of evidence-based de-escalation algorithm in ventilator-associated pneumonia (VAP) will increase the rate of appropriate targeted antimicrobial therapy in order to improve patient outcomes.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Number of patients with appropriate de-escalation according to VAP algorithm, assessed at the end of data collection.", "secondaryOutcome": "1. Number of antibiotic-free days\n2. Number of ventilator-free days\n3. Number of organ dysfunctions \n4. Length of ICU stay\n5. Length of hospital stay\n6. Rate of super-infections with multidrug resistant (MDR) species (P. aeruginosa, methicillin-resistant S. aureus etc.)\n7. Therapy costs\n\nAll assessed at the end of data collection.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics Committee of Charit\u00e9 - University Medicine Berlin approved on the 16th February 2009 (ref: EA1/209/08)"}, "externalRefs": {"doi": "10.1186/ISRCTN80881420", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "EA1/209/08"}, "trialDesign": {"studyDesign": "Prospective observational single centre cohort study", "primaryStudyDesign": "Observational", "secondaryStudyDesign": "Cohort study", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2009-03-03T00:00:00.000Z", "overallEndDate": "2010-03-03T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "0478a2ed-46a8-443d-ae38-6321efdc803f", "name": "Augustenburger Platz 1", "address": null, "city": "Berlin", "state": null, "country": "Germany", "zip": "13353"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Intensive care unit (ICU) patients aged greater than 18 years, either sex\n2. On mechanical ventilation for greater than or equal to 48 hours \n3. Presenting with systemic inflammatory response syndrome (SIRS) and radiologically suggested new infiltrate", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "200", "totalFinalEnrolment": null, "totalTarget": "200", "exclusion": "1. Aged less than 18 years \n2. Other unknown infectious focus\n3. Severe immune suppression (defined as corticosteroid doses of more than 7.5 mg of prednisolone equivalent for longer than 30 days, or other immuno-suppressive drugs)\n4. Acquired immune deficiency syndrome (AIDS)/human immunodeficiency virus (HIV)\n5. Moribund patients", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2009-03-03T00:00:00.000Z", "recruitmentEnd": "2010-03-03T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Ventilator-associated pneumonia", "diseaseClass1": "Respiratory", "diseaseClass2": "Pneumonia, organism unspecified"}}, "interventions": {"intervention": {"description": "After distribution of the de-escalation algorithm, clinician teams will be asked to treat the patients with suspicion of VAP according to algorithm. It will be left to their discretion, whether to adhere to the algorithm in whole or in part or not at all.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18538-0", "contactId": "Contact56529_18538", "sponsorId": "Sponsor55103"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56529_18538", "title": "Prof", "forename": "Claudia", "surname": "Spies", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Augustenburger Platz 1", "city": "Berlin", "country": "Germany", "zip": "13353", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55103", "organisation": "Charit\u00e9 - University Medicine Berlin (Charit\u00e9 - Universit\u00e4tsmedizin Berlin) (Germany)", "website": "http://www.charite.de/", "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Chariteplatz 1", "city": "Berlin", "country": "Germany", "zip": "10117", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.6363.0", "rorId": "https://ror.org/001w7jn25"}, "funder": {"@id": "Funder18538-0", "name": "Charit\u00e9 - University Medicine Berlin (Charit\u00e9 - Universit\u00e4tsmedizin Berlin) (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-29T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2009-06-29T00:00:00.000Z", "#text": "67042752"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "User Evaluation of the DexCom\u2122 SEVEN.2 Continuous Glucose Monitoring System", "scientificTitle": "User Evaluation of the DexCom\u2122 SEVEN.2 Continuous Glucose Monitoring System: a single-centre prospective non-randomised masked/un-masked intervention study", "acronym": null, "studyHypothesis": "The study intends to evaluate user experience with the DexCom\u2122 SEVEN.2 Continuous Glucose Monitoring System in the home environment and the effect of its use on glycaemic control.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "To evaluate improvement in glycaemic variability in children, adolescents, and young adults, particularly in the reduction of the number of hypo- and hyper-glycaemic events, reduction of time spent outside of euglycemia glucose range, and reduction of glucose variability (standard deviation) through use of the DexCom\u2122 SEVEN.2 Continuous Glucose Monitoring System, between masked and un-masked period.", "secondaryOutcome": "To evaluate user experience with the DexCom\u2122 SEVEN.2 Continuous Glucose Monitoring System. The HbA1C level will also be evaluated; the unmasked baseline phase A1C will serve as a self-control for the subjects.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics Committee of Hannover Medical School approved on the 28th November 2008"}, "externalRefs": {"doi": "10.1186/ISRCTN67042752", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "Protocol Nr. 5181"}, "trialDesign": {"studyDesign": "Single-centre prospective non-randomised masked/un-masked intervention study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Quality of life"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-12-15T00:00:00.000Z", "overallEndDate": "2009-04-15T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "dae4495e-f029-4345-be49-8ac2e3629ee1", "name": "Janusz-Korczak-Allee 12", "address": null, "city": "Hannover", "state": null, "country": "Germany", "zip": "30173"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Documented type 1 diabetes mellitus diagnosis at least 1 year prior to enrolment\n2. Recommended to perform daily self-monitoring blood glucose testing\n3. Performing multiple daily insulin injections, or has been on an insulin pump, for at least 6 months prior to enrolment\n4. Less than 24 years of age, either sex\n5. Willing and capable of following the protocol and instructions provided by the investigator \n6. Available for the entire study duration of 63 days and for follow up on scheduled study visit days\n7. Provided written informed consent", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "55", "totalFinalEnrolment": null, "totalTarget": "Target enrolment: 55 patients with the aim of 50 completion", "exclusion": "1. Subject has had an episode of severe hypoglycaemia in past four weeks prior to enrolment\n2. Allergy to medical grade adhesives\n3. Any medical condition or medication, which in the investigator\u0092s opinion, may compromise patient safety \n4. Participation in any other study which may affect glucose measurements or glucose management\n5. Known, suspected or planning pregnancy during study participation", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-12-15T00:00:00.000Z", "recruitmentEnd": "2009-04-15T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Type 1 diabetes mellitus", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Non-insulin-dependent diabetes mellitus"}}, "interventions": {"intervention": {"description": "During baseline Phase 1 (duration 21 days), subjects will be masked to the display of the DexCom\u2122 SEVEN.2 continuous glucose readings. Subjects will calibrate the DexCom\u2122 SEVEN.2 Receiver using standard fingerstick blood glucose testing with test strips. Subjects will manage their diabetes based upon the blood glucose measurements using their established regimen prescribed by their healthcare professional prior to study enrolment.  \n\nAt the end of the Phase 1, subjects will return to the clinic to have their DexCom\u2122 SEVEN.2 systems set to display continuous glucose readings and enable low and high glucose alarms. Subjects will continue for the rest of the study using the DexCom\u2122 SEVEN.2 system as an adjunctive device to guide glucose management according to its intended use and warnings given in the User's Guide along with the advice of the study Investigator.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18756-0", "contactId": "Contact56749_18756", "sponsorId": "Sponsor55323"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56749_18756", "title": "Prof", "forename": "Thomas", "surname": "Danne", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Janusz-Korczak-Allee 12", "city": "Hannover", "country": "Germany", "zip": "30173", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55323", "organisation": "DexCom Inc. (USA)", "website": "http://www.dexcom.com", "sponsorType": "Industry", "contactDetails": {"address": "6340 Sequence Drive", "city": "San Diego", "country": "United States of America", "zip": "92121", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.480089.d", "rorId": "https://ror.org/03ra42c27"}, "funder": {"@id": "Funder18756-0", "name": "DexCom Inc. (USA)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-17T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2009-06-17T00:00:00.000Z", "#text": "89512790"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Better balance - fall prevention among elderly people", "scientificTitle": "Randomised controlled trial to test the effects of, respectively, health coaching and an integrative district nurse approach for preventing falls in elderly people living in the community", "acronym": null, "studyHypothesis": "Health coaching and integrative district nurse approaches (two separate interventions) tailored to elderly people having experienced fall accidents and living in the community are, compared to usual care control groups, both expected to:\n1. Reduce the rate of falls (primary endpoint), measured by self-evaluation and registered hospital admissions\n2. Reduce the risk of falling, measured by selected functional tests\n3. Reduce the use of selected primary care services", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Number of falls in a twelve months period from inclusion date, measured through self-assessment.", "secondaryOutcome": "1. Functional performance nine months after inclusion. Selected balance and strengths tests indicating fall risks.\n2. Fear of falling questionnaire (FES-I), quality of life questionnaire\n3. Use of selected primary care services in a nine month period after inclusion (emergency calls, district healthcare, delivery of food, etc.,)\n4. Hospital contacts in a nine month period after inclusion", "trialWebsite": "http://www.bedrebalance.dk", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Scientific Ethics Committee of Copenhagen, Denmark gave approval on the 13th April 2007 (ref: H-C-2007-0002)"}, "externalRefs": {"doi": "10.1186/ISRCTN89512790", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Prevention"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-05-01T00:00:00.000Z", "overallEndDate": "2009-04-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Denmark"}, "trialCentres": {"trialCentre": {"@id": "4186eeb4-5eed-4e2a-8f26-8d76ba2c08f4", "name": "Department og Integrated Health Care", "address": null, "city": "Copenhagen NV", "state": null, "country": "Denmark", "zip": "2400"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Community-dwelling people aged 65+ years, either sex\n2. Fall episodes registered/known by trial partners at Hospital Units and Community Units\n3. Speaking Danish or English, no interpreter needed", "ageRange": "Senior", "gender": "Both", "targetEnrolment": "180", "totalFinalEnrolment": null, "totalTarget": "One hundred and eighty (180) patients", "exclusion": "1. Participation in other clinical trials on falls prevention \n2. Hospital admission due to the most recent fall accident (prior to inclusion)", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2007-05-01T00:00:00.000Z", "recruitmentEnd": "2009-04-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Fall prevention, elderly people living in the community", "diseaseClass1": "Other", "diseaseClass2": "Fall prevention"}}, "interventions": {"intervention": {"description": "1. Health coaching program: 6 months collaboration with professional health coach; maximum of 10 hours of coaching, maximum of 15 sessions in total, of which two are face-to-face meetings and the rest are telephone sessions\n2. Integrative district nurse program: 3 months collaboration with district nurse; two face-to-face meetings in the home, followed by two telephone sessions", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18714-0", "contactId": "Contact56707_18714", "sponsorId": "Sponsor55280"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56707_18714", "title": "Dr", "forename": "Carsten", "surname": "Hendriksen", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department og Integrated Health Care\nBispebjerg University Hospital\nBispebjerg Bakke 23", "city": "Copenhagen NV", "country": "Denmark", "zip": "2400", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55280", "organisation": "Danish Ministry of Health and Prevention (Ministeriet for Sundhed og Forebyggelse) (Denmark)", "website": "http://www.sum.dk", "sponsorType": "Government", "contactDetails": {"address": "Slotsholmsgade 10-12", "city": "Copenhagen K", "country": "Denmark", "zip": "1216", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.467925.b", "rorId": "https://ror.org/05kxbax75"}, "funder": {"@id": "Funder18714-0", "name": "Danish Ministry of Health and Prevention (Ministeriet for Sundhed og Forebyggelse) (Denmark)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-17T00:00:00.000Z", "@version": "17", "isrctn": {"@dateAssigned": "2009-06-17T00:00:00.000Z", "#text": "25592008"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Effectiveness of tailored pain management in patients with chronic back pain", "scientificTitle": "Effectiveness of tailored pain management in subgroups according to the three-cluster solution of the multidimensional pain inventory (MPI) in patients with chronic back pain in an inpatient rehabilitation setting: a randomised controlled trial", "acronym": "RCT cBPsub", "studyHypothesis": "A combination of graded exercise therapy and cognitive behavioural therapy a priori matched to subgroups of patients based on the MPI with chronic non-specific back pain shows better short-term and long-term outcome than non-matched interventions.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Self-reported functional disability (Oswestry Disability Index), measured at T0, T2, T3 and T6.\n\nTimepoints: \nT0: 4 weeks before entry\nT1: entry to pain programme\nT2: discharge from pain programme\nT3: 3 months follow-up\nT6: one year follow-up", "secondaryOutcome": "1. Observed functional disability: the physical performance tests Back Performance Scale (BPS) and 5-Minute Walk Distance, measured at T1 and T2\n2. Global perceived effect on daily functioning, measured at T2, T3 and T6\n3. The Numeric Rating Scale (NRS) for pain, measured at T1, T2, T3 and T6\n4. The subscales \"Ability to decrease pain\", and \"Ability to control pain\" of the Coping Strategies Questionnaire (CSQ), measured at T1, T2, T3 and T6\n5. Mental health (Hospital Anxiety and Depression Scale [HADS]), measured at T1, T2, T3 and T6\n6. Pain Catastrophising Scale (PCS), measured at T1, T2, T3 and T6\n7. Treatment expectancy and credibility (Credibility/Expectancy Questionnaire [CEQ]), measured at T1\n\nTimepoints: \nT0: 4 weeks before entry\nT1: entry to pain programme\nT2: discharge from pain programme\nT3: 3 months follow-up\nT6: one year follow-up", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "1. Ethics Committee of the Health Department in Aarau gave approval on the 6th February 2009 (ref: 2008/033)\n2. Ethics Committee of the Health Department in Zurich gave approval on the 12th March 2009 (ref: 15/09)"}, "externalRefs": {"doi": "10.1186/ISRCTN25592008", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A."}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2009-01-01T00:00:00.000Z", "overallEndDate": "2012-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Switzerland"}, "trialCentres": {"trialCentre": {"@id": "987f5557-e4b4-4aa5-afbb-1369d1a57ceb", "name": "Physiotherapy Institute", "address": null, "city": "Bern", "state": null, "country": "Switzerland", "zip": "3010"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Stationary patients of RehaClinic of at least 18 years old, either sex\n2. Diagnosis of chronic back pain: at least 3 months of continuous back pain localised in the lumbar, thoracic, and/or cervical region \n3. Willingness to learn behavioural patterns and motivation to participate in graded activity exercise programs\n4. Ability to formulate realistic functional goals\n5. Sufficient cognitive abilities and German language skills to understand the content of the interventions\n6. Agreement to participate in the program and the assessment by written, signed informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "120", "totalFinalEnrolment": null, "totalTarget": "A total of 120 patients (across all arms and both study centres) will be recruited", "exclusion": "1. Severe somatic illness requiring specific treatment such as cancer, inflammatory rheumatic disease, neurological disease, pain after a recent operation (less than 6 months)\n2. Specific back pain, defined as herniated disc, ankylosing spondylitis, spondylolisthesis, spinal fracture, or other relevant neurological diseases\n3. Specific medical disorders and cardiovascular diseases, preventing participation at physical exercise\n4. Pregnancy\n5. Manifest psychiatric disorder such as dementia, psychosis, suicidality\n6. Whiplash associated disorders", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2009-01-01T00:00:00.000Z", "recruitmentEnd": "2012-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Chronic back pain", "diseaseClass1": "Musculoskeletal Diseases", "diseaseClass2": "Dorsalgia"}}, "interventions": {"intervention": {"description": "The purpose of this randomised controlled trial is to examine the effectiveness of combinations of graded activity exercise (GA) with individual cognitive behavioural therapy (CBT) in subgroups of patients with chronic non-specific back pain (CNSBP) who are hypothesised to benefit from these treatments compared with similar persons who will receive strengthening and stretching exercises and CBT in a group setting. All subjects are participants in a four week inpatient pain management program and attend 20 physiotherapy sessions and 12 sessions with a clinical psychologist.\n\n1. Control group: standard group therapies and individual physiotherapy (strength and stretching exercises)\n2. Intervention group: standard group therapies and MPI-subgroup specific individual physiotherapeutic (graded activity exercise) and psychological (cognitive behavioural therapy or systemic therapy) interventions\n\nDuration of treatment: 4 weeks inpatient rehabilitation. Booster sessions by telephone for the intervention group 3 and 7 weeks after discharge. Participants will be followed-up for 12 months after entry.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18710-0", "contactId": "Contact56703_18710", "sponsorId": "Sponsor55276"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56703_18710", "title": "Mr", "forename": "Martin L", "surname": "Verra", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Physiotherapy Institute\nInselspital, Bern University Hospital\nFreiburgstrasse", "city": "Bern", "country": "Switzerland", "zip": "3010", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+41 (0)31 632 3956"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "martin.verra@insel.ch"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor55276", "organisation": "Zurzach Rehabilitation Foundation SPA (Switzerland)", "website": "http://www.reha-clinic.ch/cms/", "sponsorType": "Research organisation", "contactDetails": {"address": "Quellenstrasse", "city": "Bad Zurzach", "country": "Switzerland", "zip": "5330", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+41 (0)56 269 5151"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "a.aeschlimann@rehaclinic.ch"}}, "privacy": "Public"}, "funder": {"@id": "Funder18710-0", "name": "Zurzach Rehabilitation Foundation SPA (Switzerland)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-05-29T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2009-05-29T00:00:00.000Z", "#text": "42288908"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Household-wide treatment for the control of head lice infestations in an impoverished community", "scientificTitle": "Impact of household-wide treatment for the control of head lice infestations in an impoverished community: a randomised observer-blinded controlled trial", "acronym": null, "studyHypothesis": "Children of families that had received household-wide head lice treatment with ivermectin remain longer without head lice infestation than children of families without treatment.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The median infestation-free period, defined as the days between baseline and the first head lice positive examination during follow-up visits. A positive head lice examination was defined as the detection of at least one viable head louse or nymph determined by diagnostic wet-combing.", "secondaryOutcome": "Analyses on individual characteristics (sex, hair length and type) and characteristics of the households (poverty, crowding) were done to measure their importance for infestation-free periods. The annual incidence was calculated/estimated.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethical Review Board of the Federal University of Cear\u00e1 approved on the 14th September 2006 (ref: 179/06). Registered in the database of the Brazilian Ministry of Health for studies involving human subjects."}, "externalRefs": {"doi": "10.1186/ISRCTN42288908", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised observer-blind controlled trial (single-centre)", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-02-01T00:00:00.000Z", "overallEndDate": "2007-03-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Brazil", "Germany"]}, "trialCentres": {"trialCentre": {"@id": "c0eeb1aa-8984-40bc-8bb8-5673845d5443", "name": "Institut for Microbiology and Hygiene", "address": null, "city": "Berlin", "state": null, "country": "Germany", "zip": "12203"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Children aged 5 - 15 years, either sex\n2. Absence of active head lice infestation determined by diagnostic wet-combing\n3. Written consent obtained from the study participants and carers", "ageRange": "Child", "lowerAgeLimit": {"@unit": "Years", "@value": "5.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "15.0"}, "gender": "Both", "targetEnrolment": "132", "totalFinalEnrolment": null, "totalTarget": "132", "exclusion": "1. Active head lice infestation during baseline examination (defined as the detection of at least one viable head louse or nymph after vigorous wet-combing)\n2. Absence from the study area for more than a week\n3. Unwillingess to participate in the study", "patientInfoSheet": null, "recruitmentStart": "2007-02-01T00:00:00.000Z", "recruitmentEnd": "2007-03-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Active head lice infestation", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Pediculosis and phthiriasis"}}, "interventions": {"intervention": {"description": "Participants (sentinels) were recruted in a holiday resort outside the endemic area where another trial had taken place immediately before the study. While still in the holiday resort but immediately before entering the study, participants had received oral ivermectin. In addition, baseline head lice status was assessed by vigorous wet-combing. \n\nHouseholds of the participating children were randomised into two groups. In the intervention group, all household members (except the head lice-free sentinels) were treated orally with ivermectin (200 \u00b5g/kg; Revectina\u00ae, Solvay Farma, Brazil) the day before the sentinels returned to their families. Treatment was repeated after 10 days. Household members of the control group remained untreated. A day after the household-wide treatment the sentinels returned from the holiday resort and were examined for the presence of head lice by wet combing every three to four days, during a period of 60 days.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": "Ivermectin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18720-0", "contactId": "Contact56713_18720", "sponsorId": "Sponsor55286"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56713_18720", "title": "Prof", "forename": "Hermann", "surname": "Feldmeier", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Institut for Microbiology and Hygiene\nCharite-University Medicine Berlin\nCampus Benjamin Franklin\nHindenburgdamm 27", "city": "Berlin", "country": "Germany", "zip": "12203", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55286", "organisation": "Mandacaru Foundation (Brazil)", "website": "http://www.mandacaru-foundation.org", "sponsorType": "Charity", "contactDetails": {"address": "Rua Jos\u00e9 Vilar de Andrade 257", "city": "Fortaleza", "country": "Brazil", "zip": "CE 60833-830", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.487456.c", "rorId": "https://ror.org/05h876969"}, "funder": {"@id": "Funder18720-0", "name": "Mandacaru Foundation (Brazil)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-05-28T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2009-05-28T00:00:00.000Z", "#text": "30202688"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations", "scientificTitle": null, "acronym": null, "studyHypothesis": "The Northern Hemisphere 2009/2010-season influenza vaccine fulfills the European Medicines Agency (EMEA) requirements for re-registration of influenza vaccines.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Immunogenicity, assessed by haemagglutination inhibition test; blood to be collected before and approximately three weeks after vaccination.", "secondaryOutcome": "Safety, assessed at baseline and at three weeks after vaccination, including a four-day adverse event questionnaire, soliciting a set of local and systemic adverse events (AEs) according to the European Medicines Agency (EMEA) specifications.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Local Medical Ethics Committee (Ethikkommission beider Basel [EKBB]), Switzerland on the 31th March 2009 (ref: 64/09)"}, "externalRefs": {"doi": "10.1186/ISRCTN30202688", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "INF-V-A003"}, "trialDesign": {"studyDesign": "Open non-randomised uncontrolled safety/efficacy study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Other", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Prevention"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2009-06-01T00:00:00.000Z", "overallEndDate": "2009-08-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Switzerland"}, "trialCentres": {"trialCentre": {"@id": "872fb159-a87a-4ac7-a31e-d3c0d03d6651", "name": "Swiss Pharma Contract Ltd", "address": null, "city": "Allschwil", "state": null, "country": "Switzerland", "zip": "4123"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Healthy female and male volunteers equal to or older than 18 years of age on the day of enrolment\n2. Written informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "110", "totalFinalEnrolment": null, "totalTarget": "110", "exclusion": "1. Pregnancy and lactation\n2. Serious adverse reaction to any influenza vaccine", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2009-06-01T00:00:00.000Z", "recruitmentEnd": "2009-08-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Influenza", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Influenza, virus not identified"}}, "interventions": {"intervention": {"description": "Biological: single dose of trivalent virosomal adjuvanted influenza vaccine (Inflexal\u00ae V). Total duration of follow-up: approximately three weeks", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Trivalent virosomal adjuvanted influenza vaccine (Inflexal\u00ae V)"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18690-0", "contactId": "Contact56683_18690", "sponsorId": "Sponsor55256"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56683_18690", "title": "Dr", "forename": "Michael", "surname": "Seiberling", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Swiss Pharma Contract Ltd\nLettenweg 118", "city": "Allschwil", "country": "Switzerland", "zip": "4123", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55256", "organisation": "Crucell, Berna Biotech Ltd (Switzerland)", "website": "http://www.crucell.com", "sponsorType": "Industry", "contactDetails": {"address": "Rehhagstrasse 79", "city": "Berne", "country": "Switzerland", "zip": "3018", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.432742.4"}, "funder": {"@id": "Funder18690-0", "name": "Crucell, Berna Biotech Ltd (Switzerland)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-05-27T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2009-05-27T00:00:00.000Z", "#text": "00745795"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Efficacy of the Talking Health Together\u2122 communication education intervention for primary care patients with chronic disease", "scientificTitle": "A multicentre, randomised trial in Ontario to evaluate the efficacy of Talking Health Together\u2122 (THT in Practice), a communication education intervention for primary care patients with chronic disease", "acronym": "THT In Practice", "studyHypothesis": "We hypothesise that both Prepare, Ask, Check and Express (PACE) Talking Health Together\u2122 (THT) education approaches compared to usual care will improve patient participation in medical encounters with their primary care physician. We also hypothesise that the combined THT e-Learning followed by workshop approach compared to the THT e-Learning alone approach will be more efficacious in improving patient participation in medical encounters.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Evaluate the impact, compared to usual care, of a PACE training intervention of patients with chronic disease using one of two THT education approaches (either e-Learning only or e-Learning followed by a workshop) on patients' participation in primary care encounters assessed after intervention. We also will compare the impact of the THT e-Learning only approach to the THT e-Learning followed by workshop approach in the same way. This will be assessed by coding and analysis of audio-taped dialogue between the patient and the doctor at second of two doctor visits. Two published methodologies will be used: RIAS and MEDICODE.", "secondaryOutcome": "1. Physician satisfaction with the doctor-patient encounter\n2. Physician sense of partnership with patients\n3. Patient perception of quality of doctor-patient communication and relationship\n4. Patient confidence in own ability to communicate effectively with their doctor\n5. Patient perception of the management of their chronic disease(s)\n6. Patient recall of discussions of lifestyle recommendations and chronic disease medications discussed during the encounter\n\nAssessed by questionnaires filled out by both patients and physicians at both visit 1 and visit 2.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Institutional Review Board Services gave approval on the 9th January 2009"}, "externalRefs": {"doi": "10.1186/ISRCTN00745795", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Prospective multicentre randomised three-arm parallel group study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "GP practice"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2009-03-15T00:00:00.000Z", "overallEndDate": "2010-07-06T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Canada"}, "trialCentres": {"trialCentre": {"@id": "5e687947-03fa-4cca-86a2-91622ce9c9f3", "name": "4400 Earnscliffe", "address": null, "city": "Montreal", "state": null, "country": "Canada", "zip": "H4A 3E8"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "To be eligible to participate in the study, male or female patients of participating physicians must:\n1. Be aged 40 years of age or greater\n2. Have clinical documentation of diagnosis of at least one of the following pharmacologically-treated chronic conditions for which standard disease measures are considered to not be to target: \n2.1. Type II diabetes mellitus as defined by the Canadian Diabetes Association Clinical Practice Guidelines (haemoglobin A1C greater than 7.0)\n2.2. Hypertension defined as either resting office diastolic blood pressure of greater than 90 mmHg or resting office systolic blood pressure of greater than 140 mmHg and for diabetics: either resting office diastolic blood pressure of greater than 80 mmHg or resting office systolic blood pressure of greater than 130 mmHg as per Canadian Hypertension Education Program (CHEP) Guidelines\n2.3. Hypercholesterolaemia as defined by the Hyperlipidaemia Canadian Consensus Guidelines (Low risk patients: low density lipoprotein [LDL] greater than or equal to 5.0 mmol/l or total cholesterol [TC]/high density lipoprotein [HDL] greater than or equal to 6 mmol/l, and high risk patients: LDL greater than 2 mmol/l or TC/HDL greater than 4 mmol/l)\n3. Receive a prescribed medication for the chronic disease for which they  were included in the study (i.e., hypertension, diabetes and hypercholesterolaemia)\n4. Fill their prescriptions for the chronic disease for which they were included in the study at a pharmacy where the prescription information is available in the RxCanada\u00ae Inc. database\n5. Have a routine clinic follow-up visit scheduled within three to six months of study enrolment\n\nAll participating patients will complete an informed consent form before initiation of any study related procedures.", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "360", "totalFinalEnrolment": null, "totalTarget": "360", "exclusion": "1. Patients in the active phase of cancer treatment (i.e. chemotherapy or radiotherapy at time of this study)\n2. Previous enrolment in the present study\n3. Pregnant or lactating women\n4. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)\n5. Involvement in any other clinical study or adherence program\n6. Inability to read or write in English\n7. Inability to carry out the encounter with their physician in English without need of assistance\n8. Uncomfortable using a computer for routine activities such as regular access to the web and e-mail", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2009-03-15T00:00:00.000Z", "recruitmentEnd": "2010-07-06T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Type II diabetes mellitus, hypertension, hypercholesterolaemia", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Non-insulin-dependent diabetes mellitus"}}, "interventions": {"intervention": {"description": "The three intervention arms are as follows:\n1. THT e-Learning module alone\n2. THT e-Learning module followed by THT nurse-led workshop\n3. Control Group - wsual care (no THT intervention or other intervention)\n\nTotal duration of treatment is the length of time it takes to complete the on-line training for the e-Learning arm (approximately 45 minutes to 1 hour) and the length of time it takes to do the workshop (approximately 3 hours).  For the third arm that gets usual care, there is no intervention.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18624-0", "contactId": "Contact56616_18624", "sponsorId": "Sponsor55190"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56616_18624", "title": "Dr", "forename": "Marie-Therese", "surname": "Lussier", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "4400 Earnscliffe", "city": "Montreal", "country": "Canada", "zip": "H4A 3E8", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "mtlussier@videotron.ca"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor55190", "organisation": "AstraZeneca Inc. (Canada)", "website": "http://www.astrazeneca.com/", "sponsorType": "Industry", "contactDetails": {"address": "c/o Duncan Jewell\n1004 Middlegate Road", "city": "Mississauga", "country": "Canada", "zip": "L4Y 1M4", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "duncan.jewell@astrazeneca.com"}}, "privacy": "Public", "gridId": "grid.424144.3", "rorId": "https://ror.org/04n8fbz89"}, "funder": {"@id": "Funder18624-0", "name": "AstraZeneca Inc. (Canada)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-05-26T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2009-05-26T00:00:00.000Z", "#text": "12262174"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "27G-Quincke\u00ae vs 27G-Pencil-Point\u00ae spinal needles for spinal saddle block", "scientificTitle": "Comparison of 27G-Quincke\u00ae vs 27G-Pencil-Point\u00ae spinal needles and 10 vs 30 minutes fixation time for spinal saddle block regarding the incidence of post-dural puncture headache", "acronym": null, "studyHypothesis": "The incidence of post-dural puncture headache in spinal saddle block seems to be associated with the time given for fixation of the local anaesthetic. Under the assumption of an elevated cerebro-spinal-fluid pressure in the lumbar spine in the sitting position we hypothesised that (a) using a 27G-Pencil-Point\u00ae spinal needle instead of a 27G-Quincke-type\u00ae spinal needle AND (b) leaving the patient in the upright position for fixation of the local anaesthetic for 10 instead of 30 minutes would reduce the incidence of post-dural-puncture headache.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Incidence of post-dural puncture headache and other complications, measured one week after anaesthesia.", "secondaryOutcome": "No secondary outcome measures", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Medical Ethics Committee II, Faculty of Medicine, Ruprecht Karl University of Heidelberg  (Medizinische Ethikkommission II: Medizinische Fakult\u00e4t Mannheim der Ruprecht-Karls-Universit\u00e4t Heidelberg), approved on 27/09/2008."}, "externalRefs": {"doi": "10.1186/ISRCTN12262174", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled single-centre trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-09-01T00:00:00.000Z", "overallEndDate": "2009-08-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "ffb46414-4b98-4f4f-89fd-6096b4985337", "name": "Universit\u00e4tsmedizin Mannheim", "address": null, "city": "Mannheim", "state": null, "country": "Germany", "zip": "69167"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients (male/female) with minor perianal surgery\n2. Age 18-80 years\n3. American Society of Anesthesiologists (ASA) physical status I-III\n4. No contraindications for spinal anaesthesia", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "80.0"}, "gender": "Both", "targetEnrolment": "400", "totalFinalEnrolment": null, "totalTarget": "400", "exclusion": "1. Contraindications for spinal anaesthesia\n2. Allergy to local anaesthetics", "patientInfoSheet": null, "recruitmentStart": "2008-09-01T00:00:00.000Z", "recruitmentEnd": "2009-08-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Post-dural puncture headache", "diseaseClass1": "Nervous System Diseases", "diseaseClass2": "Postprocedural disorders of nervous system, not elsewhere classified"}}, "interventions": {"intervention": {"description": "Patients are randomised 1:1:1:1 to:\n\nA: 27-gauge Quincke\u00ae needle, being left in the upright postion for 10 minutes\nB: 27-gauge Quincke\u00ae needle, being left in the upright postion for 30 minutes\nC: 27-gauge Pencil-Point\u00ae needle, being left in the upright postion for 10 minutes\nD: 27-gauge Pencil-Point\u00ae needle, being left in the upright postion for 30 minutes\n\nPatients receive a questionnaire and phone call one week later  to obtain information about satisfaction and occurring complications. The time for the performance of the spinal anaesthesia and problems with the handling of the spinal needle are recorded by the anaesthesiologist.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder18512-0", "Funder18512-1"], "contactId": "Contact56503_18512", "sponsorId": "Sponsor55076"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56503_18512", "title": "Dr", "forename": "Marc D", "surname": "Schmittner", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Universit\u00e4tsmedizin Mannheim\nKlinik f\u00fcr An\u00e4sthesiologie und Operative Intensivmedizin\nTheodor-Kutzer-Ufer 1-3", "city": "Mannheim", "country": "Germany", "zip": "69167", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor55076", "organisation": "B. Braun Melsungen AG (Germany)", "website": "http://www.bbraun.com", "sponsorType": "Industry", "contactDetails": {"address": "Carl-Braun-Strasse 1", "city": "Melsungen", "country": "Germany", "zip": "34212", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.462046.2", "rorId": "https://ror.org/04nxj7050"}, "funder": [{"@id": "Funder18512-0", "name": "University of Heidelberg (Germany) - main funder", "fundRef": null}, {"@id": "Funder18512-1", "name": "B. Braun Melsungen AG (Germany) - provided the spinal needles", "fundRef": null}]}, {"trial": {"@lastUpdated": "2009-05-26T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2009-05-26T00:00:00.000Z", "#text": "44297014"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A phase III randomised, double-blind, active comparator-controlled clinical trial to study the safety and efficacy of lurasidone in subjects with schizophrenia (PEARL 3 extension study)", "scientificTitle": null, "acronym": "PEARL 3 Extension Study", "studyHypothesis": "Lurasidone HCl is a compound being developed for the treatment of schizophrenia.  This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long-term among schizophrenic outpatients with chronic schizophrenia.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Primary efficacy endpoint: \n1.1. Time to relapse of psychotic symptoms in subjects to measure the long-term maintenance of antipsychotic efficacy of lurasidone compared with quetiapine XR.\n\n2. Primary safety endpoints: \nThe proportion of subjects with: \n2.1. Adverse Events (AEs) \n2.2. Discontinuations due to AEs \n2.3. Serious Adverse Events (SAEs) \n\nAEs will be monitored throughout the study until Month 12.", "secondaryOutcome": "Efficacy endpoints of interest: \nTime to relapse of psychotic symptoms. Mean change from D1050233 baseline in the Positive and Negative Syndrome Scale (PANSS): positive score, negative score, and excitability score. PANSS will be carried out at Month 3, 6, 9, 12 in this extension study.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "USA: Copernicus Group IRB, approved on 05/09/2008.\n\nAll other centres will seek ethics approval before recruitment of the first participant."}, "externalRefs": {"doi": "10.1186/ISRCTN44297014", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "D1050234"}, "trialDesign": {"studyDesign": "Randomised double-blind active comparator-controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-12-01T00:00:00.000Z", "overallEndDate": "2010-12-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Colombia", "Germany", "India", "Philippines", "Romania", "Russian Federation", "Ukraine", "United States of America"]}, "trialCentres": {"trialCentre": {"@id": "19556cf9-dfd6-4b48-8083-0e970c1ed1d7", "name": "Dainippon Sumitomo Pharma America Inc.", "address": null, "city": "New Jersey", "state": null, "country": "United States of America", "zip": "07024"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Screening for the present study will take place after subjects' participation in Study D1050233 has been completed, and after providing informed consent. \n\nPrincipal inclusion criteria: \n1. Males and females 18-75 years of age inclusive \n2. Provide written informed consent \n3. Completed all required assessments on the final study visit in Study D1050233 \n4. Suitable for treatment in an outpatient setting", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "75.0"}, "gender": "Both", "targetEnrolment": "240", "totalFinalEnrolment": null, "totalTarget": "Approximately 240", "exclusion": "1. Any chronic organic disease of the central nervous system (CNS) (other than schizophrenia)\n2. Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-12-01T00:00:00.000Z", "recruitmentEnd": "2010-12-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Schizophrenia", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Schizophrenia"}}, "interventions": {"intervention": {"description": "Subjects who meet entry criteria will continue treatment with either flexibly dosed lurasidone or quetiapine XR based on their treatment assignment in Study D1050233 in a double-blinded fashion. Subjects treated with placebo in Study D1050233 will be treated with lurasidone. \n\nArm 1: Lurasidone HCI 40-160 mg/day orally for 12 months \nArm 2: Quetiapine XR 200-800 mg/day orally for 12 months", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase III", "drugNames": "Lurasidone HCl, quetiapine XR"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18272-0", "contactId": "Contact56260_18272", "sponsorId": "Sponsor54829"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56260_18272", "title": "Dr", "forename": "Kaushik", "surname": "Sarma", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Dainippon Sumitomo Pharma America Inc.\nOne Bridge Plaza\nSuite 510\nFort Lee", "city": "New Jersey", "country": "United States of America", "zip": "07024", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54829", "organisation": "Dainippon Sumitomo Pharma America Inc. (USA)", "website": "http://www.ds-pharma.co.jp/english", "sponsorType": "Industry", "contactDetails": {"address": "One Bridge Plaza\nSuite 510 \nFort Lee", "city": "New Jersey", "country": "United States of America", "zip": "07024", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.422116.2", "rorId": "https://ror.org/04vwbmb32"}, "funder": {"@id": "Funder18272-0", "name": "Dainippon Sumitomo Pharma Co. Ltd. (Japan)", "fundRef": "http://dx.doi.org/10.13039/501100002975"}}, {"trial": {"@lastUpdated": "2009-06-18T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2008-06-12T00:00:00.000Z", "#text": "88405796"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Strategies for the prevention of dengue (Estrategias para la prevencion del Dengue)", "scientificTitle": "A cluster randomised trial evaluating community involvement in Aedes control and dengue prevention", "acronym": null, "studyHypothesis": "An integrated community-based environmental management strategy is more effective in terms of reductions in entomological indices in comparison to routine Aedes control.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Aedes infestation levels, assessed every 11 days over the total duratin of follow-up (13 months): \n1. House Indices (HI): number of houses positive for at least one container with Aedes aegypti immature stages/100 inspected houses \n2. Breteau Indices (BI): number of containers positive for Aedes aegypti immature stages/100 inspected houses \n3. Pupal Indices (PI): number of Aedes aegypti pupae/inhabitant \n\nIn cycles of 11 days, the National Vector Control programme conducted routine entomological surveys in all dwellings of the municipality. This provided the entomological information for all clusters for the period of January 2005-February 2006.", "secondaryOutcome": "1. Proportion of breeding sites positive for first and second instar larvae. Data were collected as for the primary outcome measures every 11 days over 13 months. \n2. Percentage of blocks (approximately 20-50 houses per block) repeatedly positive for larvae. Data were collected as for the primary outcome measures every 11 days over 13 months. \n3. Level of community participation based on the Rifkin criteria, assessed 12 months after the start of interventions", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics Committee of the Pedro Kouri Institute (Comit\u00e9 de \u00e9tica y revision del Instituto Pedro Kouri),  Havana, Cuba (affiliated to the Ministry of Health [MINSAP]), approved in September 2003 (ref: 0103015)"}, "externalRefs": {"doi": "10.1186/ISRCTN88405796", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "DGCD-FA2-95900-4"}, "trialDesign": {"studyDesign": "Single-centre cluster randomised controlled trial (blinding not possible).", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Prevention"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-09-01T00:00:00.000Z", "overallEndDate": "2007-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Belgium", "Cuba"]}, "trialCentres": {"trialCentre": {"@id": "d8366794-55c7-4ad5-85f0-cbd64bdc9525", "name": "Institute of Tropical Medicine", "address": null, "city": "Antwerp", "state": null, "country": "Belgium", "zip": "2000"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Circumscriptions (i.e. neighbourhoods) of central urban Guantanamo \n2. Community approval", "ageRange": "Other", "gender": "Both", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "32 circumscriptions of each approximately 500 houses", "exclusion": "1. Circumscriptions without community approval", "patientInfoSheet": null, "recruitmentStart": "2004-09-01T00:00:00.000Z", "recruitmentEnd": "2007-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Aedes aegypti infestation/ dengue fever", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Dengue fever [classical dengue]"}}, "interventions": {"intervention": {"description": "Intervention communities: A community-based environmental management approach combined with the routine national dengue vector control programme. Dengue control activities were identified, designed, planned and executed by the community itself, with the support of newly set-up local Community Working Groups. \nControl communities: Routine Aedes aegypti control programme (entomological surveillance, source reduction, selective adulticiding and health education)\n\nTotal duration of interventions/ follow-up: 13 months", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19509031 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "fc32ee44-36f9-4bdd-ba35-287094b20f56", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-06-09T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19509031"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": ["Funder17781-0", "Funder17781-1"], "contactId": "Contact55757_17781", "sponsorId": "Sponsor54327"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55757_17781", "title": "Prof", "forename": "Patrick", "surname": "Van der Stuyft", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Institute of Tropical Medicine\nEpidemiology and Disease Control Unit, Public Health Department\nNationalestraat 155", "city": "Antwerp", "country": "Belgium", "zip": "2000", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "pvdstuyft@itg.be"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor54327", "organisation": "Directorate-General for Development Co-operation (DGDC) (Belgium)", "website": "http://www.dgic.be/en/index.html", "sponsorType": "Government", "contactDetails": {"address": "FOD Buitenlandse Zaken\nBuitenlandse Handel en\nOntwikkelingssamenwerking\nKarmelietenstraat 15", "city": "Brussels", "country": "Belgium", "zip": "1000", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": [{"@id": "Funder17781-0", "name": "Directorate-General for Development Co-operation (DGDC) (Belgium) (project ref: 95900) (framework agreement between the Institute of Tropical Medicine of Belgium and of Cuba)", "fundRef": null}, {"@id": "Funder17781-1", "name": "Ministry of Health (MINSAP) (Cuba)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2009-06-04T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2006-09-29T00:00:00.000Z", "#text": "25473161"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Comparison of cricothyrotomy on a simulator versus manikin: a randomised cross over study", "scientificTitle": null, "acronym": null, "studyHypothesis": "What is the difference in cricothyrotomy training on a simulator compared with a manikin?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Outcome measured by time taken  and skills developed.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN25473161", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0295165955"}, "trialDesign": {"studyDesign": "Randomised cross over study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-06-01T00:00:00.000Z", "overallEndDate": "2005-11-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "7633832c-44fa-43bb-a7c0-9d50475e13fc", "name": "Consultant - Anaesthesia", "address": null, "city": "Coventry", "state": null, "country": "United Kingdom", "zip": "CV2 2DX"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "All doctors undergoing cricothyrotomy training", "ageRange": "Adult", "gender": "Not Specified", "targetEnrolment": "70", "totalFinalEnrolment": null, "totalTarget": "70 doctors", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "2005-06-01T00:00:00.000Z", "recruitmentEnd": "2005-11-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Surgery: Cricothyrotomy", "diseaseClass1": "Surgery", "diseaseClass2": "Cricothyrotomy"}}, "interventions": {"intervention": {"description": "Cricothyrotomy training on a simulator compared to cricothyrotomy training with a manikin", "interventionType": "Procedure/Surgery", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17845655 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "e13a0450-0979-46d9-a6da-2da9b9bc81f6", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-10-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17845655"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder15633-0", "contactId": "Contact53566_15633", "sponsorId": "Sponsor52113"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact53566_15633", "title": "Dr", "forename": "C", "surname": "Mendonca", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Consultant - Anaesthesia\nAnaesthetics Department\nWalsgrave Hospital", "city": "Coventry", "country": "United Kingdom", "zip": "CV2 2DX", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor52113", "organisation": "Record Provided by the NHSTCT Register - 2006 Update - Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health, Richmond House, 79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder15633-0", "name": "University Hospitals Coventry and Warwickshire NHS Trust (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-01T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2006-08-22T00:00:00.000Z", "#text": "47339346"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Phase I-/II-study of Hyperfractionated-Accelerated Radiation Therapy plus Cetuximab plus Cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck", "scientificTitle": null, "acronym": "HART-CIS-CET", "studyHypothesis": "An improvement of loco-regional disease control by addition of cetuximab (CET) to hyperfractionated-accelerated radiation therapy (HART) and cisplatin (CIS) is expected.\n\nAs of 01/06/2009 this record has been updated. All updates can be found in the relevant fields under the above update date. At this time, the anticipated end date of this trial was extended from 31/12/2007 to 31/12/2012, and the initial target number of participants was 67.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Phase I:\nDefinition of maximum tolerated dose (MTD) of cisplatin in HART-CIS-CET\n\nPhase II:\nDetermination of the two year progression-free survival (PFS)", "secondaryOutcome": "Phase I:\n1. Evaluation of toxicity (according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0)\n2. Determination of objective tumour response rate (ORR) (according to Response Evaluation Criteria In Solid Tumors [RECIST])\n3. Determination of one, two and five year PFS, loco-regional progression-free survival (LPFS) and overall survival (OS)\n\nPhase II:\n1. Determination of one and five year-PFS\n2. Determination of one, two and five year LPFS and OS\n3. Determination of ORR (according to RECIST)\n4. Evaluation of toxicity (according to CTCAE version 3.0)", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics commission of the Medical Faculty of the Martin-Luther-University Halle-Wittenberg gave approval on the 10th June 2005."}, "externalRefs": {"doi": "10.1186/ISRCTN47339346", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "Final 01/15.02.05"}, "trialDesign": {"studyDesign": "Open-label, non-randomised phase I/II study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Non randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-06-10T00:00:00.000Z", "overallEndDate": "2012-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Germany", "Netherlands"]}, "trialCentres": {"trialCentre": {"@id": "64b43c14-5d6b-43a6-a860-7266c7597a0d", "name": "Universit\u00e4tsklinikum Rostock A\u00f6R", "address": null, "city": "Rostock", "state": null, "country": "Germany", "zip": "18059"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients with histologically confirmed unresectable squamous cell carcinoma (SCC) of the oral cavity (no lip), oropharynx, hypopharynx or larynx (stage III/IVa or b)\n2. Unidimensionally measurable lesion\n3. Signed informed consent\n4. Karnofsky Performance Status more than or equal to 70%\n5. Aged between 18 and 70 years\n6. Curative treatment intent\n7. Negative serum or urine pregnancy test (women of childbearing potential)\n8. Adequate bone marrow, hepatic and renal function\n\nAll patients should have a dental examination and appropriate, dental therapy if required prior to the beginning of radiotherapy. A percutaneous gastrostomy (PEG) is required.", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "92", "totalFinalEnrolment": null, "totalTarget": "Added 01/06/2009: Phase I: 18, Phase II: 74", "exclusion": "1. Unknown primary cancer, nasopharynx cancer or salivary gland cancer\n2. Metastatic disease\n3. Another cancer within five years of study entry\n4. Serious concomitant disease or medical condition\n5. Pregnancy or lactation\n6. Women of child-bearing potential with unclear contraception\n7. Previous treatment with chemotherapy, radiotherapy or surgery in head and neck\n8. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening\n9. Life expectancy less than three months\n10. Contraindications to receive cisplatin or cetuximab\n11. Previous exposure to monoclonal antibodies and/or epidermal growth factor receptor (EGFR)-targeted therapy\n12. Social situations that limit the compliance with study requirements", "patientInfoSheet": null, "recruitmentStart": "2005-06-10T00:00:00.000Z", "recruitmentEnd": "2012-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Squamous cell carcinoma (SCC)", "diseaseClass1": "Cancer", "diseaseClass2": "Carcinoma of the skin"}}, "interventions": {"intervention": {"description": "Phase I:\n1. HART: 30/2 Gy once daily, then twice daily 1/4 Gy to a total dose of 70/6 Gy\n2. Chemotherapy: cisplatin - escalating doses (20, 30, 35, 40 mg/sqm), once weekly (typically on Monday), week one to six intravenous (iv) over a one hour infusion on days 1, 8, 15, 22, 29, 36\n3. Antibody: cetuximab - loading dose 400 mg/sqm iv over a 120-min infusion on day 7 followed by subsequent weekly doses of 250 mg/sqm weeks one to six iv over a one hour infusion on days 1, 8, 15, 22, 29, 36\n\nPhase II:\n1. HART: see phase I\n2. Chemotherapy: cisplatin at the recommended dose level defined in phase I\n3. Antibody: see phase I", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase I/II", "drugNames": "Cetuximab, cisplatin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder13702-0", "contactId": "Contact51377_13702", "sponsorId": "Sponsor49781"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact51377_13702", "title": "Dr", "forename": "Kuhnt", "surname": "Thomas", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Universit\u00e4tsklinikum Rostock A\u00f6R\nZentrum f\u00fcr Radiologie\nKlinik und Poliklinik f\u00fcr Strahlentherapie\nS\u00fcdring 75", "city": "Rostock", "country": "Germany", "zip": "18059", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor49781", "organisation": "Martin-Luther-University Halle-Wittenberg (Germany)", "website": "http://www.kks-halle.de", "sponsorType": "University/education", "contactDetails": {"address": "Medical Faculty\nMagdeburger Strasse 27", "city": "Halle/Saale", "country": "Germany", "zip": "06120", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.9018.0", "rorId": "https://ror.org/05gqaka33"}, "funder": {"@id": "Funder13702-0", "name": "Merck Pharma GmbH Darmstadt (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-01T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2006-06-30T00:00:00.000Z", "#text": "64676790"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Influence of anthroposophical supportive medicine on treatment-related toxicity in children receiving cancer therapy", "scientificTitle": null, "acronym": null, "studyHypothesis": "Anthroposophic supportive medicine can reduce the incidence and the cause of treatment-related toxicity in children receiving cancer therapy.\n\nAs of 01/06/2009 this record was updated to include an extension to the anticipated end date of this trial; the initial end date was 31/03/2009.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration", "secondaryOutcome": "Quality of life questionnaires", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "The trial was accepted by the Local Ethics Committee of Charite University Medicine, Berlin on18/08/2005"}, "externalRefs": {"doi": "10.1186/ISRCTN64676790", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "09-2004 PaedonkoChar"}, "trialDesign": {"studyDesign": "Randomised, controlled, phase IV trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Quality of life"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-11-01T00:00:00.000Z", "overallEndDate": "2012-03-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "c60bb19f-e309-46ce-93bd-aea26ab0c2d7", "name": "Charit\u00e9 - University Medicine Berlin", "address": null, "city": "Berlin", "state": null, "country": "Germany", "zip": "13353"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "The trial will be open to patients being treated according to current protocols for solid tumours, lymphoma and leukaemia in the German Society for Paediatric Oncology and Haematology (GPOH), aged between 1 and 18 years", "ageRange": "Child", "lowerAgeLimit": {"@unit": "Years", "@value": "1.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "340", "totalFinalEnrolment": null, "totalTarget": "340", "exclusion": "Current use of any experimental therapy", "patientInfoSheet": null, "recruitmentStart": "2005-11-01T00:00:00.000Z", "recruitmentEnd": "2012-03-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Solid tumours, lymphoma and leukaemia", "diseaseClass1": "Cancer", "diseaseClass2": "Leukaemia of unspecified cell type"}}, "interventions": {"intervention": {"description": "We plan to include 340 children with malignancies to be randomly allocated to an arm with anthroposophically-supported medicine in addition to standard treatment compared to an arm with standard treatment alone.\n\nThe anthroposophical therapy, which includes mistletoe, will be partly given preventively in parallel to chemotherapy, and partly as an exactly defined intervention stand-by medication.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Phase IV", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder14716-0", "Funder14716-1", "Funder14716-2"], "contactId": "Contact52477_14716", "sponsorId": "Sponsor50992"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52477_14716", "title": "Dr", "forename": "Georg", "surname": "Seifert", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Charit\u00e9 - University Medicine Berlin\nMittelallee 6a\nAugustenburger Platz 1", "city": "Berlin", "country": "Germany", "zip": "13353", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)30 450 666087"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "georg.seifert@charite.de"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50992", "organisation": "Helixor Heilmittel GmbH and Co. (Germany)", "website": "http://www.helixor.de", "sponsorType": "Industry", "contactDetails": {"address": "Helixor Heilmittel GmbH and Co. KG\nFischerm\u00fchle 1", "city": "Rosenfeld", "country": "Germany", "zip": "72348", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)74 289 350"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "jschierholz@helixor.de"}}, "privacy": "Public", "gridId": "grid.467394.b", "rorId": "https://ror.org/02thwp314"}, "funder": [{"@id": "Funder14716-0", "name": "Helixor Heilmittel GmbH (Germany)", "fundRef": null}, {"@id": "Funder14716-1", "name": "Weleda AG (Germany)", "fundRef": null}, {"@id": "Funder14716-2", "name": "WALA Heilmittel GmbH (Germany)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2009-06-02T00:00:00.000Z", "@version": "24", "isrctn": {"@dateAssigned": "2006-05-12T00:00:00.000Z", "#text": "67515515"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Randomized controlled trial comparing the impact of supplementary feeding with either ready-to-use therapeutic food or corn-soy blend among malnourished anti-retroviral therapy clients in Malawi", "scientificTitle": null, "acronym": null, "studyHypothesis": "Among wasted human immunodeficiency virus (HIV)-infected adults starting anti-retroviral therapy (ART), those that receive short-term, nutrient-dense ready-to-use therapeutic food (RUTF), may show an increase in body weight, experience fewer significant clinical events and higher CD4 counts, than their counterparts that receive corn-soy blend (CSB)", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Body mass index and fat free body mass as measured by the bioelectrical impedance at 3, 6, 9 and 12 months", "secondaryOutcome": "1. The number and severity of clinical events at 3, 6, 9 and 12 months\n2. Monthly change in quality of life assessment\n3. The change from baseline in the CD4 count at three months\n4. Serum albumin and hematocrit at three months\n5. Viral load at three months\n6. Compliance with ART regimen\n7. Cost-effectiveness of the two dietary regimens", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "University of Malawi College of Medicine Research Ethics Committee (COMREC), reference number: P.04/05/350; Federal Wide Assurance Number 00001395 and registration number 00001157. Also reviewed and approved by the Human Studies Committee, Washington University School of Medicine, St. Louis, Missouri."}, "externalRefs": {"doi": "10.1186/ISRCTN67515515", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "P.04/05/350"}, "trialDesign": {"studyDesign": "Randomized single-blind (investigator) controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-01-06T00:00:00.000Z", "overallEndDate": "2007-05-06T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Malawi", "United States of America"]}, "trialCentres": {"trialCentre": {"@id": "ffb6ca1c-4e1a-4e95-a400-bad28920f86f", "name": "Washington University in St. Louis School of Medicine", "address": null, "city": "Missouri", "state": null, "country": "United States of America", "zip": "63110"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Adults (>18 years old) diagnosed with acquired immune deficiency syndrome (AIDS) and meeting eligibility criteria for ART according to the National HIV treatment guidelines\n2. World Health Organisation (WHO) stage III or IV or any WHO stage and a CD4 count <200 /mm^3 and beginning treatment with ART with a body mass index (BMI) of <18.5", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "450", "totalFinalEnrolment": null, "totalTarget": "450 (2 groups of 225 each)", "exclusion": "1. Age <18 years\n2. Pregnant or lactating women\n3. Enrolment in any other supplementary feeding program", "patientInfoSheet": null, "recruitmentStart": "2006-01-06T00:00:00.000Z", "recruitmentEnd": "2007-05-06T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Malnutrition and HIV infection", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "HIV and malnutrition"}}, "interventions": {"intervention": {"description": "375 g CSB (300 g corn and 75 g soy flour fortified with vitamins and minerals), or 260 g peanut-based RUTF (26% dried skimmed milk, 27% sugar, 26% peanut paste, 20% vegetable oil, and 1.5% vitamins) and mineral premix per person per day during their first three months of ART", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Ready-to-use therapeutic food or corn-soy blend"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19465470 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "d225c3b8-8259-40b5-b948-72ed34253e3f", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-05-22T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19465470"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder14635-0", "contactId": "Contact52393_14635", "sponsorId": "Sponsor50906"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52393_14635", "title": "Prof", "forename": "Mark John", "surname": "Manary", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Washington University in St. Louis School of Medicine\nDepartment of Pediatrics\nDivision of Emergency Medicine\nSt. Louis Children's Hospital\nOne Children's Place\nSt. Louis", "city": "Missouri", "country": "United States of America", "zip": "63110", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "manary@kids.wustl.edu"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50906", "organisation": "St. Louis Children's Hospital (USA)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Department of Pediatrics\nDivision of Emergency Medicine\nSt. Louis Children's Hospital\nOne Children's Place\nSt. Louis", "city": "Missouri", "country": "United States of America", "zip": "63110", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "manary@kids.wustl.edu"}}, "privacy": "Public", "gridId": "grid.416775.6", "rorId": "https://ror.org/00qw1qw03"}, "funder": {"@id": "Funder14635-0", "name": "Academy for Educational Development, Washington DC (USA)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-26T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2006-03-22T00:00:00.000Z", "#text": "31849226"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Promotion of cerebral plasticity by mirror therapy - evaluation of a new therapy approach for neurological rehabilitation", "scientificTitle": "Effect of mirror therapy early after stroke: a randomised, single-blinded, placebo-controlled trial", "acronym": null, "studyHypothesis": "Patients after a first-ever, single stroke in the middle cerebral artery (MCA) area show a significantly better outcome when treated for six weeks with additional mirror training compared to six weeks of additional training with a direct view of their affected hand.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Fugl Meyer (FM) score after six weeks of intervention", "secondaryOutcome": "1. Action research arm test (ARAT) score after six weeks of intervention\n2. Functional independence measure (FIM) score after six weeks of intervention", "trialWebsite": "http://www.spiegeltraining.de", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics Committee of the Physicians Chamber North Rhein (Arztekammer Nordrhein) (General Medical Council) approved on the 14th July 2004 (ref: 2004189)"}, "externalRefs": {"doi": "10.1186/ISRCTN31849226", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "0315"}, "trialDesign": {"studyDesign": "Randomised single-blinded placebo-controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Quality of life"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-07-01T00:00:00.000Z", "overallEndDate": "2006-08-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "cc8829f7-2f9e-4344-b8fc-7399faf7574a", "name": "MEDIAN Klinik Berlin", "address": null, "city": "Berlin", "state": null, "country": "Germany", "zip": "D-14089"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. First ever, single stroke in the MCA territory not more than eight weeks prior to study inclusion\n2. Aged 30 to 80 years\n3. Severe hemiparesis\n4. Cardiovascular stability for participation at several therapy units a day\n5. Communication level allowing obedience to therapy protocol\n6. Written informed consent", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "40", "totalFinalEnrolment": null, "totalTarget": "40", "exclusion": "1. Multiple strokes\n2. Significant hemorrhagic imbibition\n3. Prior hemicranectomy\n4. Restricted mobility of the upper extremity by orthopedic, rheumatologic or other concomitant disease", "patientInfoSheet": "Can be found at http://www.refonet.de/projekte/documents/Pat-Information-080924.pdf", "recruitmentStart": "2004-07-01T00:00:00.000Z", "recruitmentEnd": "2006-08-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "First-ever, single stroke in the MCA territory not more than eight weeks prior to study inclusion", "diseaseClass1": "Nervous System Diseases", "diseaseClass2": "Single stroke in the MCA territory"}}, "interventions": {"intervention": {"description": "Additional occupational therapy for six weeks (30 minutes a day, 5 days a week) - mirror training versus training with a direct view of the affected hand", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19074686 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "1745d83b-f98b-41ef-a9c2-8303d1604418", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-03-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19074686"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder14850-0", "contactId": "Contact52624_14850", "sponsorId": "Sponsor51156"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52624_14850", "title": "Dr", "forename": "Christian", "surname": "Dohle", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "MEDIAN Klinik Berlin \nDepartment of Neurological Rehabilitation\nCharite - University medicine Berlin\nCampus Benjamin Franklin \nKladower Damm 223", "city": "Berlin", "country": "Germany", "zip": "D-14089", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)30 36503 105/106"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dohle.berlin@median-kliniken.de"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51156", "organisation": "Refonet (Germany)", "website": "http://www.refonet.de", "sponsorType": "Industry", "contactDetails": {"address": "Burgweg 3", "city": "Bad Neuenahr-Ahrweiler", "country": "Germany", "zip": "D-53445", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)264 190 620"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "service@refonet.de"}}, "privacy": "Public", "gridId": "grid.487444.f", "rorId": "https://ror.org/04yeh2x21"}, "funder": {"@id": "Funder14850-0", "name": "Refonet (Germany) (ref: 3015)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-04T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2005-09-30T00:00:00.000Z", "#text": "22366060"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "An open pilot trial of the effects of acupuncture in the treatment of knee osteoarthritis.", "scientificTitle": null, "acronym": null, "studyHypothesis": "In an open study, can acupuncture be shown to have an analgesic effect for patients with osteoarthritis of the knee?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Patients Global Assessment of Efficacy\n2. Investigator Global Assessment of Efficacy\n3. 100m Visual Analogue Scale for Pain Assessment \n4. WOMAC Index\n5. Kellgren & Lawrence Scale for radiological assessment of osteoarthritis", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN22366060", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0265041788"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Single-centre", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-07-01T00:00:00.000Z", "overallEndDate": "2007-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "9759f779-c83f-479f-9787-9b172294ee90", "name": "Rheumatology", "address": null, "city": "Birmingham", "state": null, "country": "United Kingdom", "zip": "B29 6JD"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "This is a pilot study - the size of any effect not known. Volunteers will be recruited from the rheumatology outpatients clinics at Selly Oak Hospital. We anticipate about 10 patients per group will be sufficient to enable a power calculation to be made. They must have osteoarthritis of the knee, and find that their pain is not well controlled by conventional medicine. They must be over 18 years of age.", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Not Specified", "targetEnrolment": "30", "totalFinalEnrolment": null, "totalTarget": "30", "exclusion": "Patients will be excluded if they have any of the following: rheumatoid arthritis, Gout, psoriatic arthritis, osteoarthritis of the hip, patients with pacemakers fitted, patients with known metal allergies, patients with an history of prosthetic or damaged valves, patients with hemophilia, patients taking an anticoagulant or oral corticosteroid, patients suffering with dementia or other psychiatric disease, patients with Grade I or IV on the Kellgren & Lawrence scale, patients with uncontrolled diabetes and patients with a skin disease likely to affect the use of the acupuncture needles.", "patientInfoSheet": null, "recruitmentStart": "2003-07-01T00:00:00.000Z", "recruitmentEnd": "2007-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Musculoskeletal Diseases: Knee osteoarthritis", "diseaseClass1": "Musculoskeletal Diseases", "diseaseClass2": "Knee osteoarthritis"}}, "interventions": {"intervention": {"description": "Open pilot study looking at patients who have osteoarthritis of their knee and whose pain is not well-controlled on conventional treatment. The patients would be asked to take part for a period of 5 weeks. Possible patients must be over 18 years of age, not women of child-bearing age, not patients with pacemakers fitted. Patients will be randomised into one of three groups:\n1. Patients receiving acupuncture alone\n2. Patients receiving acupuncture as well as their conventional therapy\n3. Patients continuing on their conventional therapy", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15077933 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "60f7cbe4-9a85-441f-8003-99207fd1bd75", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2004-03-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/15077933"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder14048-0", "contactId": "Contact51624_14048", "sponsorId": "Sponsor50215"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact51624_14048", "title": "Dr", "forename": "RW", "surname": "Jubb", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Rheumatology\nSelly Oak Hospital", "city": "Birmingham", "country": "United Kingdom", "zip": "B29 6JD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor50215", "organisation": "Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder14048-0", "name": "University Hospital Birmingham NHS Trust (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-19T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2005-09-26T00:00:00.000Z", "#text": "35629817"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "The Peri-Operative Epidural Trial pilot study", "scientificTitle": "Peri-operative epidural in patients with moderate or high risk for cardiorespiratory events who are undergoing non-cardiothoracic surgery: a randomised controlled trial", "acronym": "POET", "studyHypothesis": "Enrolling patients into the above study is still feasible in the current clinical setting.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Rates of enrolment, follow-up, and crossover.", "secondaryOutcome": "1. Combined 30-day outcome of all-cause mortality, nonfatal myocardial infarction, cardiac arrest, postoperative pneumonia, and respiratory failure\n2. Other clinical outcomes: deep vein thrombosis, pulmonary embolism, transient ischemic attacks, stroke, and congestive heart failure during first 30 post-operative days\n3. Safety outcomes: clinically significant bradycardia or hypotension", "trialWebsite": "http://www.crsu.ca", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Clinical Research Ethics Board of the University of British Columbia on the 31st March 2005."}, "externalRefs": {"doi": "10.1186/ISRCTN35629817", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": "NCT00221260", "protocolSerialNumber": "MCT-73644"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-05-01T00:00:00.000Z", "overallEndDate": "2006-04-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Canada"}, "trialCentres": {"trialCentre": {"@id": "9f9c3cea-3f17-4289-add5-e920c3536c5b", "name": "University of British Columbia", "address": null, "city": "Vancouver", "state": null, "country": "Canada", "zip": "V5Z 4E3"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Any patient undergoing non-cardiopulmonary surgery who:\n1. Is greater than or equal to 45 years old, either sex\n2. Has an expected length of stay greater than or equal to 48 hours\n3. Is undergoing a procedure amenable to postoperative epidural analgesia\n4. Fulfils any six criteria for moderate to high cardiorespiratory risk", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "250", "totalFinalEnrolment": null, "totalTarget": "250", "exclusion": "1. Is pregnant or planning to become pregnant before surgery\n2. Has a contraindication to epidural analgesia\n3. Had a prior adverse reaction to local anesthetics or narcotics\n4. Had coronary artery bypass graft surgery with complete revascularisation in the preceding 5 years and has no evidence of cardiac ischemia since the procedure\n5. Has pneumonia in the preoperative period\n6. Is intubated or mechanically ventilated prior to surgery\n7. Has concomitant life-threatening disease likely to limit life expectancy to less than 30 days", "patientInfoSheet": null, "recruitmentStart": "2005-05-01T00:00:00.000Z", "recruitmentEnd": "2006-04-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Postoperative cardio-respiratory complications", "diseaseClass1": "Circulatory System", "diseaseClass2": null}}, "interventions": {"intervention": {"description": "Control:\nIntraoperative general anesthesia and postoperative intravenous narcotic analgesia. \n\nIntervention:\nIntraoperative neuraxial (epidural or spinal) \u00b1 general anesthesia and postoperative epidural analgesia. \n\nTrial details received: 12 September 2005", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19247497 Results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "7cec892b-5efe-4ff3-a9f5-24144780386a", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-06-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19247497"}, "description": "Results", "productionNotes": null}}, "parties": {"funderId": "Funder13775-0", "contactId": "Contact51476_13775", "sponsorId": "Sponsor49871"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact51476_13775", "title": "Dr", "forename": "Peter T", "surname": "Choi", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University of British Columbia\nDepartment of Anesthesiology\nPharmacology & Therapeutics\n910 West 10th Avenue, Room 3200", "city": "Vancouver", "country": "Canada", "zip": "V5Z 4E3", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+1 604-875-4111 (68433)"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "petert.choi@vch.ca"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor49871", "organisation": "Vancouver Coastal Health Research Institute, University of British Columbia (Canada)", "website": null, "sponsorType": "Not defined", "contactDetails": {"address": "828 West 10th Avenue", "city": "Vancouver", "country": "Canada", "zip": "V5Z 1L8", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "cheryl.davies@vch.ca"}}, "privacy": "Public", "gridId": "grid.17091.3e", "rorId": "https://ror.org/03rmrcq20"}, "funder": {"@id": "Funder13775-0", "name": "Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-73644)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-05-18T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2004-09-30T00:00:00.000Z", "#text": "13459412"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "An open-label study followed by a double-blind randomised comparison of the effect of sedation versus melatonin combined with sedation in children undergoing magnetic resonance imaging (MRI)", "scientificTitle": null, "acronym": null, "studyHypothesis": "How effective is melatonin when combined with other sedatives for sedation of children for MRI?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Time taken to fall asleep for scanning", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN13459412", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0012128200"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-06-01T00:00:00.000Z", "overallEndDate": "2003-09-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "ee95c111-3ffd-43ad-b7dd-fd5c92e2876c", "name": "Anaesthetics", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "WC1N 3JH"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Children undergoing MRI", "ageRange": "Child", "gender": "Not Specified", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "Not provided at time of registration", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "2003-06-01T00:00:00.000Z", "recruitmentEnd": "2003-09-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Not Applicable: Magnetic resonance imaging (MRI)", "diseaseClass1": "Other", "diseaseClass2": "Magnetic resonance imaging (MRI)"}}, "interventions": {"intervention": {"description": "1. Melatonin and combined sedatives \n2. Melatonin", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "melatonin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16782974 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "31992ca9-45d6-4c0b-b9b0-123b9f7787e7", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2006-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/16782974"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder12751-0", "contactId": "Contact49948_12751", "sponsorId": "Sponsor48583"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact49948_12751", "title": "Dr", "forename": "M R J", "surname": "Sury", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Anaesthetics\nGreat Ormond Street Hospital\nGreat Ormond Street", "city": "London", "country": "United Kingdom", "zip": "WC1N 3JH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7405 9200 ext 5399"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor48583", "organisation": "Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder12751-0", "name": "Great Ormond Street Hospital for Children NHS Trust/Institute of Child Health (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-29T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2004-09-30T00:00:00.000Z", "#text": "73824847"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A double-blind, cross-over study evaluating the efficacy of localised pulsed magnetic field therapy (PMFT) for pain relief in volunteers", "scientificTitle": null, "acronym": null, "studyHypothesis": "Investigate the direct effect of pulsed magnetic field therapy on pain.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Detect whether the application of pulsed magnetic field therapy (PMFT) causes a difference in visual analogue scale (VAS) pain.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN73824847", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0123138598"}, "trialDesign": {"studyDesign": "Randomised controlled trial cross-over study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-12-23T00:00:00.000Z", "overallEndDate": "2005-11-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "4b858c2e-92c9-4d40-b6b4-8bcb2b96d1c3", "name": "University Hospitals of Leicester", "address": null, "city": "Leicester", "state": null, "country": "United Kingdom", "zip": "LE1 4PW"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Fit and healthy male volunteers aged between 18 and 40 years.", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Male", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "Not provided at time of registration", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "2003-12-23T00:00:00.000Z", "recruitmentEnd": "2005-11-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Signs and Symptoms: Pain", "diseaseClass1": "Signs and Symptoms", "diseaseClass2": "Pain"}}, "interventions": {"intervention": {"description": "Localised pulsed magnetic field vs sham", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17519258 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "be7a5d80-c0ea-47e2-8ce6-6aade0aaf0ef", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17519258"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder12439-0", "contactId": "Contact50195_12439", "sponsorId": "Sponsor48583"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact50195_12439", "title": "Prof", "forename": "David", "surname": "Rowbotham", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University Hospitals of Leicester\nc/o Research and Development Office\nLeicester General Hospital NHS Trust", "city": "Leicester", "country": "United Kingdom", "zip": "LE1 4PW", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor48583", "organisation": "Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder12439-0", "name": "University Hospitals of Leicester NHS Trust (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-01T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2004-09-30T00:00:00.000Z", "#text": "49417400"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Within-patient randomised cross-over control trial of alteplase versus heparin locks to maintain central line patency in haemodialysed children", "scientificTitle": null, "acronym": null, "studyHypothesis": "Not provided at time of registration", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration.", "secondaryOutcome": "Not provided at time of registration.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN49417400", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0503135048"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-02-23T00:00:00.000Z", "overallEndDate": "2004-04-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "14569bb9-cc2e-44a4-902c-9515229d4b7d", "name": "Royal Victoria Infirmary", "address": null, "city": "Newcastle upon Tyne", "state": null, "country": "United Kingdom", "zip": "NE1 4LP"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Not provided at time of registration", "ageRange": "Child", "gender": "Not Specified", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "Not provided at time of registration", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "2004-02-23T00:00:00.000Z", "recruitmentEnd": "2004-04-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Urological and Genital Diseases: Haemodialysis", "diseaseClass1": "Urological and Genital Diseases", "diseaseClass2": "Haemodialysis"}}, "interventions": {"intervention": {"description": "Alteplase versus heparin locks to maintain central line patency in haemodialysed children.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Alteplase, heparin"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17068072 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "29ef322f-ddae-4c88-a610-b166934b20ca", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2007-06-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/17068072"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder12452-0", "contactId": "Contact49942_12452", "sponsorId": "Sponsor48583"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact49942_12452", "title": "Dr", "forename": "M", "surname": "Coulthard", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Royal Victoria Infirmary\nQueen Victoria Road", "city": "Newcastle upon Tyne", "country": "United Kingdom", "zip": "NE1 4LP", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor48583", "organisation": "Department of Health", "website": "http://www.dh.gov.uk/Home/fs/en", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder12452-0", "name": "Newcastle upon Tyne Hospitals NHS Trust (UK)", "fundRef": "http://dx.doi.org/10.13039/501100003776"}}, {"trial": {"@lastUpdated": "2009-06-01T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2004-01-23T00:00:00.000Z", "#text": "83655837"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Quantification of the impact of pulmonary rehabilitation in patients with moderate and severe Chronic Obstructive Pulmonary Disease (COPD)", "scientificTitle": null, "acronym": null, "studyHypothesis": "Not provided at time of registration", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "The study protocol was approved by the East London and City Health Authority Ethics Committee and all patients gave written consent."}, "externalRefs": {"doi": "10.1186/ISRCTN83655837", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1995-01-01T00:00:00.000Z", "overallEndDate": "1998-03-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "37672e81-04f3-47bf-b3bd-16126bcf7074", "name": "Academic Department of Respiratory Medicine", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "E2 9JX"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "COPD patients", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "Not provided at time of registration", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "1995-01-01T00:00:00.000Z", "recruitmentEnd": "1998-03-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Respiratory tract diseases: Chronic obstructive pulmonary disease", "diseaseClass1": "Respiratory", "diseaseClass2": "Chronic obstructive pulmonary disease"}}, "interventions": {"intervention": {"description": "1. Exercise plus education\n2. Education alone (control)\nEducation and exercise programmes for the moderately disabled patients were carried out in a hospital out-patient setting. Severely disabled patients were all treated at home. Those in the exercise group received an individualised training programme.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "1998 Results article in http://www.ncbi.nlm.nih.gov/pubmed/9727786 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "44f4d8f3-ff09-4b90-8845-c3fc24be35bd", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "1998-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/9727786"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder5816-0", "contactId": "Contact7214_5816", "sponsorId": "Sponsor5354"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact7214_5816", "title": "Dr", "forename": "Jadwiga", "surname": "Wedzicha", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Academic Department of Respiratory Medicine\nSt. Bartholomew's and the Royal London School of Medicine and Dentistry\nThe London Chest Hospital\nBonner Road", "city": "London", "country": "United Kingdom", "zip": "E2 9JX", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor5354", "organisation": "Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)", "website": "http://www.doh.gov.uk", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health\nRichmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder5816-0", "name": "NHS Physical and Complex Disabilities National Research and Development Programme (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-01T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2004-01-23T00:00:00.000Z", "#text": "21277091"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment", "scientificTitle": null, "acronym": null, "studyHypothesis": "To determine the efficacy of teaching patients with bipolar disorder (manic-depressive psychosis) to identify early symptoms of relapse and seek prompt treatment from health services.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Time to first manic or depressive relapse\n2. Number of manic or depressive relapses\n3. Social functioning examined by standardised interviews every six months for 18 months", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "The study was approved by a medical ethics committee in each NHS trust. Each patient gave written informed consent to the trial."}, "externalRefs": {"doi": "10.1186/ISRCTN21277091", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1994-03-01T00:00:00.000Z", "overallEndDate": "1997-04-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "03350b65-9ce7-4501-89bf-b1f399ec1443", "name": "Department of Community Psychiatry", "address": null, "city": "Manchester", "state": null, "country": "United Kingdom", "zip": "M20 8LR"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. A lifetime diagnosis of bipolar disorder elicited by a trained research assistant using a standardised psychiatric interview\n2. Two or more relapses\n3. One in the previous 12 months\n4. Aged 18 to 75 years", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "69", "totalFinalEnrolment": null, "totalTarget": "69", "exclusion": "1. An inability to read or write in English\n2. Drug or alcohol misuse or dependence as a primary problem\n3. An organic cerebral cause for bipolar disorder, e.g., multiple sclerosis or stroke", "patientInfoSheet": null, "recruitmentStart": "1994-03-01T00:00:00.000Z", "recruitmentEnd": "1997-04-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Schizophrenia and other psychoses", "diseaseClass1": "Mental and Behavioural Disorders", "diseaseClass2": "Schizophrenia"}}, "interventions": {"intervention": {"description": "7 - 12 intervention treatment sessions from a research psychologist plus routine care versus routine care only.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "1999 Results article in http://www.ncbi.nlm.nih.gov/pubmed/9888904 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "49a40c23-35ba-431c-a9ee-2f309cab1eab", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "1999-01-16T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/9888904"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder6180-0", "contactId": "Contact7457_6180", "sponsorId": "Sponsor5355"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact7457_6180", "title": "Dr", "forename": "Richard", "surname": "Morriss", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Community Psychiatry\nUniversity of Manchester\nWithington Hospital", "city": "Manchester", "country": "United Kingdom", "zip": "M20 8LR", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor5355", "organisation": "NHS R&D Regional Programme Register - Department of Health (UK)", "website": "http://www.doh.gov.uk", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health\nRichmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder6180-0", "name": "NHS Executive North West (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-01T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2004-01-23T00:00:00.000Z", "#text": "12392192"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Care of minor injuries by emergency nurse practitioners or junior doctors: a randomised controlled trial", "scientificTitle": null, "acronym": null, "studyHypothesis": "To compare the package of the care for patients with minor injuries provided by nurse practitioners with that provided by junior doctors.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Adequacy of care provided by the nurse practitioner or junior doctor.", "secondaryOutcome": "1. Patient's satisfaction with the quality of their care\n2. Improvement and return to usual activities\n3. Need for unplanned follow-up", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethical approval was obtained for the study from the local research ethics committee."}, "externalRefs": {"doi": "10.1186/ISRCTN12392192", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1997-02-10T00:00:00.000Z", "overallEndDate": "1997-08-04T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "fcbb2403-0fff-436f-8c8d-c2352e436080", "name": "Department of Accident and Emergency Medicine", "address": null, "city": "Sheffield", "state": null, "country": "United Kingdom", "zip": "S5 7AU"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Patients presenting at accident and emergency department with minor injuries.", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "Not provided at time of registration", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "1997-02-10T00:00:00.000Z", "recruitmentEnd": "1997-08-04T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Burns", "diseaseClass1": "Injury, Occupational Diseases, Poisoning", "diseaseClass2": "Burns"}}, "interventions": {"intervention": {"description": "Care by junior doctor versus care by nurse practitioner", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "1999 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10533859 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "69121c22-d6ec-4463-b910-6cc5091ec9d5", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "1999-10-16T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/10533859"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder6186-0", "contactId": "Contact7379_6186", "sponsorId": "Sponsor5355"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact7379_6186", "title": "Dr", "forename": "J", "surname": "Wardrope", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of Accident and Emergency Medicine\nNorthern General Hospital", "city": "Sheffield", "country": "United Kingdom", "zip": "S5 7AU", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor5355", "organisation": "NHS R&D Regional Programme Register - Department of Health (UK)", "website": "http://www.doh.gov.uk", "sponsorType": "Government", "contactDetails": {"address": "The Department of Health\nRichmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7307 2622"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "dhmail@doh.gsi.org.uk"}}, "privacy": "Public"}, "funder": {"@id": "Funder6186-0", "name": "NHS Executive Trent (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-01T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2003-09-12T00:00:00.000Z", "#text": "13416422"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A randomised study comparing the effectiveness of entonox and morphine analgesia for the removal of chest drains in postoperative children at Great Ormond Street Hospital", "scientificTitle": null, "acronym": null, "studyHypothesis": "Is there a difference between the pain relief provided by entonox and morphine for the removal of chest drains?", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN13416422", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N0012108168"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1998-05-01T00:00:00.000Z", "overallEndDate": "2004-02-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "44f93015-d3ce-47f4-8283-76248c37d917", "name": "c/o Research & Development Office", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "WC1N 1EH"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Children who have had chest drains", "ageRange": "Child", "gender": "Not Specified", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "Not provided at time of registration", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "1998-05-01T00:00:00.000Z", "recruitmentEnd": "2004-02-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Signs and Symptoms: Pain", "diseaseClass1": "Signs and Symptoms", "diseaseClass2": "Pain"}}, "interventions": {"intervention": {"description": "Interviews. Random allocation to (A) Pain relief treatment (B) Placebo.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "entonox  and morphine"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16490095 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "3a77d03a-894f-49f1-9cb1-1d845e6f530f", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2006-03-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/16490095"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder5202-0", "contactId": "Contact6909_5202", "sponsorId": "Sponsor5287"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact6909_5202", "title": "Miss", "forename": "EA", "surname": "Bruce", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "c/o Research & Development Office\nInstitute of Child Health\n30 Guilford Street", "city": "London", "country": "United Kingdom", "zip": "WC1N 1EH", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)20 7405 9200"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor5287", "organisation": "Department of Health (UK)", "website": "http://www.doh.gov.uk", "sponsorType": "Government", "contactDetails": {"address": "Richmond House\n79 Whitehall", "city": "London", "state": null, "country": "United Kingdom", "zip": "SW1A 2NL", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder5202-0", "name": "Great Ormond Street Hospital for Children NHS Trust / Institute of Child Health (UK)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-06-11T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2003-04-25T00:00:00.000Z", "#text": "33678610"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A randomised controlled trial (RCT) to compare minimally invasive glucose monitoring devices to conventional monitoring in the management of insulin treated diabetes mellitus.", "scientificTitle": null, "acronym": "MITRE", "studyHypothesis": "Primary Objectives 1-3, Secondary Objectives 4-7:\n1. To compare the benefits of the GlucoWatch and CGMS Minimed on glycemic control relative to conventional monitoring and an attention control.\n2. To assess patient acceptability and ease of use of  the new technologies. \n3. To model the long-term health benefits and costs and cost-effectiveness of these technologies.\n4. To assess the impact of the devices on health care utilisation for diabetes related illnesses e.g. hypoglycemia, ketosis.\n5. To assess impact of monitoring devices on patient satisfaction with care, attitudes toward diabetes and quality of life.\n6. To assess the extent to which demographic factors (e.g. age, ethnicity) and individual differences in health cognitions influence outcome.\n7. To assess the reliability of the glucowatch in clinical practice using available data.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration.", "secondaryOutcome": "Not provided at time of registration.", "trialWebsite": "http://www.ctu.mrc.ac.uk/studies/mitre.asp", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration."}, "externalRefs": {"doi": "10.1186/ISRCTN33678610", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "HTA 01/13/03"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Not Specified"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-12-01T00:00:00.000Z", "overallEndDate": "2008-08-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["England", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "fc818526-4e94-4cbe-a84d-6b626d94a74f", "name": "Diabetes & Endocrinology", "address": null, "city": "London", "state": null, "country": "United Kingdom", "zip": "W1T 3AA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Diabetics", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "404", "totalFinalEnrolment": null, "totalTarget": "Added as of 10/09/07: Accrual target: 400; Accrual count: 404", "exclusion": "Not provided at time of registration.", "patientInfoSheet": null, "recruitmentStart": "2002-12-01T00:00:00.000Z", "recruitmentEnd": "2008-08-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Nutritional, metabolic and endocrine diseases: Diabetes", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Diabetes"}}, "interventions": {"intervention": {"description": "Please note that, as of 14 January 2008, the anticipated start and end dates of this trial have been updated from 1 April 2002 and 31 March 2005 to 1 December 2002 and 31 August 2008, respectively. \n\nInterventions:\nThis will be a 4 arm RCT:\nGroup 1. GlucoWatch\nGroup 2. Continuous Glucose Monitoring System (CGMS) Minimed\nGroup 3. Attention control with a frequency of nurse feedback sessions the same as Groups 1 and 2\nGroup 4. Standard care i.e. 6 monthly clinic review", "interventionType": "Device", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19476724 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "6c3a23e0-a299-4f0c-8de6-5584ac9c821b", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2009-05-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/19476724"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder1701-0", "contactId": "Contact5199_1701", "sponsorId": "Sponsor5079"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact5199_1701", "title": "Dr", "forename": "Steven", "surname": "Hurel", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Diabetes & Endocrinology\nUniversity College London Hospitals Foundation Trust\nMortimer Street", "city": "London", "country": "United Kingdom", "zip": "W1T 3AA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)207 380 9029"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "s.hurel@ucl.ac.uk"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor5079", "organisation": "Department of Health (UK)", "website": "http://www.dh.gov.uk/en/index.htm", "sponsorType": "Government", "contactDetails": {"address": "Quarry House\nQuarry Hill", "city": "Leeds", "state": null, "country": "United Kingdom", "zip": "LS2 7UE", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+44 (0)1132 545 843"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "Sheila.Greener@doh.gsi.gov.uk"}}, "privacy": "Public", "gridId": "grid.57981.32", "rorId": "https://ror.org/03sbpja79"}, "funder": {"@id": "Funder1701-0", "name": "NIHR Health Technology Assessment Programme - HTA (UK)", "fundRef": null}}]}}